Coherus Oncology Reports Tagmokitug Safety Profile With No New Signals
Coherus Oncology said Tagmokitug has an acceptable and manageable safety profile, with no new safety signals.
Related stories
Buyers Agree to Acquire 75% of B & S International for Up to HKD 289 Million
Buyers agreed to acquire a 75% stake in B & S International for up to HKD 289 million.
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
Jinko Power Q3 Net Profit Falls 95.96% Year Over Year
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
ACAC Investment Agrees to Sell 25% of B&S International Shares
ACAC Investment agrees to sell 25% of B&S International’s issued shares; the headline also names others without identifying them.
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
Blue Owl Co-CEO Says Firm Owns Infrastructure Critical to Digital Economy Growth
Blue Owl co-CEO Lipschultz said the company owns physical infrastructure critical to the digital economy's growth.
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
Norwegian Cruise Line Raises Full-Year Profit Outlook; Shares Rise
Norwegian Cruise Line shares rose as much as 12.64% after the company raised its full-year profit outlook.
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC
L3Harris Reports Record $53.2 Billion Backlog After $19.3 Billion in 3Q Orders
L3Harris received $19.3 billion in orders in the third quarter, bringing its backlog to a record $53.2 billion. The report adds to a series of record backlogs among defense contrac
M impact | EQUITY | Oct 29, 2026, 02:11 PM UTC